TRANSCODE THERAPEUTICS INC (RNAZ) Stock Overview
USA - NASDAQ:RNAZ - US89357L5012 - Common Stock
RNAZ Key Statistics, Chart & Performance
The current stock price of RNAZ is 14.92 USD. In the past month the price increased by 32.86%. In the past year, price decreased by -97.37%.
RNAZ Latest News, Press Relases and Analysis
RNAZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.42 | 400.78B | ||
| AMGN | AMGEN INC | 13.56 | 159.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.12 | 104.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.47 | 60.33B | ||
| ARGX | ARGENX SE - ADR | 90.32 | 51.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.14 | 34.93B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 24.78B | ||
| BIIB | BIOGEN INC | 8.89 | 20.86B |
Related stock screener links
About RNAZ
Company Profile
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-04-28. The company is focused on defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a well-documented biomarker of metastasis. The company is also developing a portfolio of other RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. Its preclinical programs include TTX-siPDL1, is an siRNA-based modulator of programmed death-ligand 1, or PD-L1, TTX-RIGA, is an RNA-based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment and TTX-siMYC is a siRNA-based inhibitor of c-MYC.
Company Info
TRANSCODE THERAPEUTICS INC
6 Liberty Square, #2382
Boston MASSACHUSETTS US
CEO: Robert Michael Dudley
Employees: 7
Phone: 18573016857
TRANSCODE THERAPEUTICS INC / RNAZ FAQ
What is the stock price of TRANSCODE THERAPEUTICS INC today?
The current stock price of RNAZ is 14.92 USD. The price increased by 0.47% in the last trading session.
What is the ticker symbol for TRANSCODE THERAPEUTICS INC stock?
The exchange symbol of TRANSCODE THERAPEUTICS INC is RNAZ and it is listed on the Nasdaq exchange.
On which exchange is RNAZ stock listed?
RNAZ stock is listed on the Nasdaq exchange.
What is TRANSCODE THERAPEUTICS INC worth?
TRANSCODE THERAPEUTICS INC (RNAZ) has a market capitalization of 12.38M USD. This makes RNAZ a Nano Cap stock.
How many employees does TRANSCODE THERAPEUTICS INC have?
TRANSCODE THERAPEUTICS INC (RNAZ) currently has 7 employees.
What are the support and resistance levels for TRANSCODE THERAPEUTICS INC (RNAZ) stock?
TRANSCODE THERAPEUTICS INC (RNAZ) has a support level at 10.59 and a resistance level at 14.93. Check the full technical report for a detailed analysis of RNAZ support and resistance levels.
Is TRANSCODE THERAPEUTICS INC (RNAZ) expected to grow?
The Revenue of TRANSCODE THERAPEUTICS INC (RNAZ) is expected to decline by -100% in the next year. Check the estimates tab for more information on the RNAZ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRANSCODE THERAPEUTICS INC (RNAZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNAZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNAZ, evaluating the profitability, health, valuation and growth aspects
- TRANSCODE THERAPEUTICS INC (RNAZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRANSCODE THERAPEUTICS INC (RNAZ) Sales and EPS estimates to see what analysts future expectations are.
- TRANSCODE THERAPEUTICS INC (RNAZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRANSCODE THERAPEUTICS INC (RNAZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRANSCODE THERAPEUTICS INC (RNAZ) Stock Chart to make your own analysis
- TRANSCODE THERAPEUTICS INC (RNAZ) Latest news and press-releases to stay up to date.
Does TRANSCODE THERAPEUTICS INC (RNAZ) stock pay dividends?
RNAZ does not pay a dividend.
What is the Price/Earnings (PE) ratio of TRANSCODE THERAPEUTICS INC (RNAZ)?
TRANSCODE THERAPEUTICS INC (RNAZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1462.72).
What is the Short Interest ratio of TRANSCODE THERAPEUTICS INC (RNAZ) stock?
The outstanding short interest for TRANSCODE THERAPEUTICS INC (RNAZ) is 7.07% of its float. Check the ownership tab for more information on the RNAZ short interest.
RNAZ Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to RNAZ. When comparing the yearly performance of all stocks, RNAZ is a bad performer in the overall market: 89.7% of all stocks are doing better.
RNAZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNAZ. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNAZ Financial Highlights
Over the last trailing twelve months RNAZ reported a non-GAAP Earnings per Share(EPS) of -1462.72. The EPS increased by 99.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -297.95% | ||
| ROE | -400.64% | ||
| Debt/Equity | 0 |
RNAZ Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.7% and a revenue growth -100% for RNAZ